Chondrolysis of the Hip (Idiopathic and Post-SCFE)

Chondrolysis is an uncommon, acquired, rapid loss of articular cartilage that narrows the joint space concentrically, all the way around the joint. In the hip it is seen in two distinct populations, and the page keeps them separate because their prevention differs.

Idiopathic chondrolysis of the hip (ICH). A rare disease of adolescents, classically girls, presenting around the early teens: the Patwardhan series of 41 cases had a mean age of 12.5 years. No reliable population incidence is available, so none is quoted; it is rare enough to be frequently misdiagnosed, which is precisely why early MRI matters.

Post-SCFE chondrolysis. The historically important form complicates slipped capital femoral epiphysis treated with in-situ fixation. In the Jofe review of 17 such hips, 14 (88%) had definite radiographic pin penetration of the femoral head, which makes penetration the classic avoidable cause.

The shoulder counterpart. Post-arthroscopic glenohumeral chondrolysis (PAGCL) is the adult iatrogenic form. In the Hansen series, 12 of 19 shoulders that received an intra-articular bupivacaine-epinephrine pain pump after a capsular procedure developed chondrolysis, an association strong enough to end the practice.

A final common pathway. Idiopathic and post-SCFE disease dominate paediatric practice, but chondrolysis is best understood as a final common pathway with several triggers. Many idiopathic cases have no identifiable trigger at all. The recognised triggers are:

• Prolonged immobilisation or joint distraction
• Untreated sepsis
• Inflammatory arthritis
• Trauma
• Burns, including severe burns
• Iatrogenic chondrotoxicity, which matters to the adult surgeon

The immune mechanism (idiopathic form). The aetiology is genuinely uncertain, which is why treatment remains anti-inflammatory and immunomodulatory rather than targeted. An abnormal, probably autoimmune, response directed at the articular cartilage is proposed, and synovial inflammation with a lymphoplasmacytic infiltrate and raised intra-articular immunoglobulins and complement have been reported. That hypothesis is the rationale for the intra-articular steroid and the recombinant TNF-receptor fusion protein used in the cited series.

The mechanical mechanism (post-SCFE form). Direct chondral injury from an intra-articular pin or implant is the classic avoidable trigger. Even without documented penetration, the altered joint mechanics and increased contact stress of the slip deformity, plus raised intra-articular pressure, can drive cartilage loss.

Iatrogenic chondrotoxicity. The best-recognised iatrogenic form is post-arthroscopic glenohumeral chondrolysis, in which a continuous intra-articular infusion of local anaesthetic (classically bupivacaine via a "pain pump"), with or without thermal or radiofrequency energy, destroys the articular cartilage over months. Local anaesthetic chondrotoxicity is concentration- and duration-dependent, which is why continuous intra-articular catheters have been abandoned. A single injection is a different exposure from a 48-hour infusion, a distinction worth making explicitly if asked.

The common pathway. Whatever the trigger, accelerated chondrocyte and matrix loss thins the cartilage globally. The result is concentric narrowing, capsular contracture and, if unchecked, fibrous ankylosis, and it is why treatment that calms inflammation and preserves motion works best before the cartilage is irreversibly lost. The underlying cartilage matrix biology is developed in our Articular Cartilage topics.

The patient. Idiopathic chondrolysis presents with a single painful, stiff hip, a claudication (antalgic) gait and pelvic tilt, without specific clinical signs. The hip has reduced range of motion and a contracture. It is a diagnosis of exclusion, and because there is no specific clinical or laboratory test the misdiagnosis rate is high.

The pattern. Cartilage is lost all around the joint, so the joint space narrows concentrically. That is what distinguishes chondrolysis from the focal loss of osteoarthritis, which narrows the superolateral weight-bearing zone, and from the femoral head collapse of avascular necrosis, in which the joint space is relatively preserved early. A young patient with a stiff hip and global narrowing should prompt the diagnosis and an early MRI, rather than a label of early osteoarthritis or transient synovitis.

View larger

Radiographs first. A properly positioned AP pelvis, so that the comparison with the other hip is fair. The conventional threshold is a joint space of less than about 3 mm, or a loss of more than half the joint space compared with the contralateral hip, in a concentric rather than focal pattern. That quantitative definition is what separates "narrowed" from "chondrolysis" when the examiner asks how you would prove it.

Early MRI is the critical test. It shows cartilage loss, effusion and often surrounding marrow and soft-tissue change before the radiographic joint space narrows (Guan). The Camarnat MRI stage guides both treatment and prognosis.

Bloods are normal by definition. FBC, ESR, CRP, rheumatoid factor, autoimmune panel and TB testing are all unremarkable in idiopathic disease. Their normality is what excludes septic arthritis, TB and JIA.

The hardware after SCFE. In any hip treated for SCFE, actively exclude intra-articular implant penetration on multiplanar imaging, because unrecognised hardware in the joint is the classic, avoidable cause of post-SCFE chondrolysis. The prevention is at the index operation: confirm with multiplanar imaging and the approach-withdrawal technique that the implant is not in the joint.

Aspiration has a role only when the picture is atypical or infection cannot be excluded clinically.

Because idiopathic chondrolysis is a diagnosis of exclusion, the examinable skill is the structured differential of a stiff, painful adolescent hip with global joint-space loss, and how each is told apart.

Each of these is developed separately in septic arthritis of the paediatric hip, tuberculous arthritis, juvenile idiopathic arthritis, avascular necrosis of the hip, Legg-Calve-Perthes disease, PVNS and haemophilia.

Largely non-operative. Treatment aims to preserve motion and control inflammation, with rest or protected weight-bearing, anti-inflammatory measures, physiotherapy to maintain range, and traction or manipulation to preserve and recover motion.

Treat early. Evidence supports active early treatment: intra-articular steroid injection, manipulation and traction immobilisation improve pain and function. Earlier-stage disease responds best. Stage II or earlier responds, while late (Stage III) narrowing responds poorly and is hard to reverse.

Remove intra-articular hardware. In post-SCFE chondrolysis, any pin or implant penetrating the joint must be removed.

Salvage for end-stage disease. Painful stiffness or ankylosis may need salvage: arthrodesis in the immature skeleton, or arthroplasty once mature. The priority remains early recognition and joint-preserving treatment, which is what protects the hip from that outcome.

Outcomes run across a spectrum from full recovery to fibrous ankylosis.

• Progressive joint degeneration. Without effective treatment the disease can progress rapidly, and the hip can degenerate in adolescence itself (Guan), with late imaging showing degeneration or ankylosis.
• Fibrous ankylosis. The end of the spectrum: the Patwardhan series still found 24% of hips painful and stiff at final follow-up despite active treatment.
• Contracture and limb-length effects. The stiff, adducted, flexed hip produces a functional leg-length discrepancy and pelvic tilt.
• Iatrogenic disease. Intra-articular hardware left penetrating the joint (post-SCFE) and continuous intra-articular local-anaesthetic infusion (PAGCL) are the avoidable causes, complications of treatment rather than of the disease.